Davy Research

Venn Life Sciences

H1 results: Solid revenues; building on its operational capability
Pharma and healthcare
Venn Life Sciences

DAVY VIEW

Venn’s interim result reflects a business in the growth phase of its development. Infrastructure and systems initiatives are being implemented to improve profitability. The management team was further strengthened with the appointment of a new COO. H1 revenues and EBITDA were adversely affected by the deferral of a late phase project to Q1 2018, which needs to be reflected in our full-year forecasts. With significant scope to increase margins in a growing sub-segment of the healthcare market, we remain confident on Venn’s long-term prospects.

Download full report with analyst certification and important disclosures
Download
Download full report with analyst certification and important disclosures
Download
  • RATINGS AND PRICE CORRECT AT TIME OF ISSUE


  • Venn Life Sciences

    Closing Price: 15.4p

  • RATING 07/06/16

  • PREVIOUS RATING N/A

Analyst(S)

COMPANY DATA

JUMP TO